5-Azacitidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: A cancer and leukemia group B pilot study

B. A. Peterson, C. D. Bloomfield, A. J. Gottlieb

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Twenty-nine adults with advanced acute nonlymphocyte leukemia were treated with an intensive chemotherapy program consisting of 5-azacitidine and zorubicin. Overall, eight patients (28%) achieved a complete remission. Although only one of 19 patients with refractory leukemia responded, seven of ten patients who were treated immediately following relapse from a prior remission achieved another complete remission. The duration of remission ranged from 5 to 33 weeks (median, 14). Treatment resulted in severe toxic reactions including myelosuppression, renal tubular dysfunction, and elevations in liver enzymes. In addition, each of the 15 patients who died of treatment- associated complications had a severe infection. This combination of 5-azacitidine and zorubicin is relatively ineffective for truly refractory leukemia, but it may be a useful alternative following relapse.

Original languageEnglish (US)
Pages (from-to)563-566
Number of pages4
JournalCancer Treatment Reports
Volume66
Issue number3
StatePublished - 1982

Fingerprint Dive into the research topics of '5-Azacitidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: A cancer and leukemia group B pilot study'. Together they form a unique fingerprint.

  • Cite this